## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.:

DEX0478US.NP

Inventors:

Wolfert et al.

Serial No.:

10/552,084

Filing Date:

December 1, 2006

Examiner:

Niebauer, Ronald T.

Customer No.:

32800

Group Art Unit:

1654

Confirmation No.:

4146

Title:

New Uses of Lp-PLA2 in Combination

to Assess Coronary Risk

Electronically Submitted via EFS-Web

Date: April 17, 2009

I hereby certify that this paper is being electronically submitted on the date indicated above to the Commissioner for Patents, U.S. Patent &

Trademark Office.

By / Mullin / / / / / / / / / / / / Typed Name: Kathleen A. Tyrrell, Reg. No. 38,350

Commissioner for Patents

U.S. Patent & Trademark Office

Dear Sir:

## Reply with Request for Continued Examination

This reply is responsive to the Final Rejection mailed October 17, 2008 setting a three (3) month statutory period for response. A Petition for a three (3) month extension of time and the requisite fee are provided herewith. Also provided herewith is a request for continued examination and the requisite fee. Please enter the following amendments, remarks and Declaration by Dr. Robert Wolfert into the record.

Attorney Docket No.: DEX0478US.NP

Inventors:

Serial No.:

Filing Date:

Page 2

DEX0478US.NP Wolfert et al.

10/552,084

December 1, 2006

Amendments to the Specification begin at page 3.

The pending claims are reflected in the listing of claims which begins on page 4 of this paper.

Remarks begin on page 10.

Attorney Docket No.: DEX0478US.NP

Inventors:

Serial No.:

Page 3

Wolfert et al. 10/552,084

Filing Date: December 1, 2006

## Amendments to the Specification:

Please replace line 1 of page 33 with the following: Table 4.10 Table 4.12

Please replace line 9 of page 33 with the following: Table 4.11 Table 4.13

Please replace the paragraph beginning at line 4 of page 34 with the following:

Cox regression analysis was performed on a variety of subpopulations with traditional risk factors. Specifically, hypertension, diabetes and smoking were examined either alone or in combination. The results show that the highest Lp-PLA2 tertile conferred a dramatic increase in risk for the diabetic subpopulation in the LDL<130 group. See Figures 10 and 11 and table 4.12 below table 4.14.

Please replace line 10 of page 34 with the following: Table 4.12 Table 4.14